All News
More evidence to support role of Tyk2 in management
of skin psoriasis.
Dr.April Armstrong
#RNL2024
@RheumNow https://t.co/9vuuhJMj36
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Amazing talk by @lihi_eder on sex differences in PsA.
#RNL2024
@RheumNow https://t.co/PW5fYLYmu5
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Crossed out all therapies that doesn’t work for skin psoriasis.
For some reason, i thought that JAKi s worked for skin psoriasis. Thanks to Dr.Armstrong for clarifying.
#RNL2024
@RheumNow https://t.co/f71qmHGLwm
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
FDA-approved biologics for skin psoriasis by April Armstrong , its always nice to hear from Derm colleagues.
#RNL2024
@RheumNow https://t.co/vTLpOim8Ct
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Impact of obesity on PsA @AlexisOgdie
Weight loss works in PsA:
5 to 10% weight loss lead to OR: 3.7 MDA responses
> 10% of body weight lead even higher odds ( 6.67). #RNL2024
@RheumNow https://t.co/73O0I7uZF4
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Sever psoriatic arthritis / psoriasis by @AlexisOgdie
#RNL2024
@RheumNow https://t.co/KbN7mnHTSd
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Treating dactylitis and enthesitis: this is a sign of aggressive disease. Dr. @AlexisOgdie will treat with high dose NSAIDS and get patients on biologics quickly. #RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Which IL17i to choose? Depends on the domain
Dr. Armstrong: For the skin, the studies show brodalumab, ixekizumab and bimekizumab are superior to secukimumab for #psoriasis
Dr. @AlexisOgdie noted we don't see much differences in these IL17i for the joints.
#RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
The differences do appear to relate to actual treatment specific differential response. As well as no difference with JAKi, there seems to be no difference in placebo response @lihi_eder @RheumNow #RNL2024 https://t.co/7H4KRvd6WG
Richard Conway RichardPAConway ( View Tweet)
Many advanced treatments appear to work less well in female patients with PsA, but JAKi seem to not demonstrate this phenomenon. Not sure what to do with this data in clinical practice but it is certainly intriguing @lihi_eder @RheumNow #RNL2024 https://t.co/GDrg715ctg
Richard Conway RichardPAConway ( View Tweet)
@AlexisOgdie @_AprilArmstrong @lihi_eder are the amazing “Hot topics in PsA” panelists. #RNL2024 @RheumNow #womenforthewin https://t.co/6V2QyGJM98
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Lihi Eder discusses the differences between sex and gender.
Sex is a biologically-based construct defining differences between male and female
Gender has socio-cultural aspects of being a man, woman, or other AND has effect on social norms/expectations
BOTH are important to… https://t.co/iceTS0w5LY https://t.co/slSQMwF91J
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Differences in PsA:
Women tend to have higher pain scores with lower pain thresholds and are more likely to report "diffuse pain" compared to men. Keep this in mind with your assessments.
Remember mimics of sacroiliitis including osteitis condensas ilii. Look at the imaging below… https://t.co/AUjkQwfSuk https://t.co/5iXx5cxm4U
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
BASDAI tends to be higher in women while there is no appreciable difference in ASDAS scoring in men compared to women.
Dr. L. Eder believes this could be due to the pain scoring in both indices.
#RNL2024 @RheumNow @lihi_eder https://t.co/i7XPenrmGG
Dr. Rachel Tate uptoTate ( View Tweet)
Did you know the majority of lecturers at #RNL2024 are women? #StrongWomenLeaders @ACRheum #RNL2024 #WomenChangingLives @rheumnow https://t.co/0TO8XUhhg5
TheDaoIndex KDAO2011 ( View Tweet)
With regard to SpA patient journey:
On average, women are diagnosed 2.3 years later than men.
Additionally, women tend to have more visits to rheumatology to reach diagnosis of PsA, AS, and RA!
Remember your inherent bias along with sex/gender disparities.
Dr. L. Eder… https://t.co/o0Hv3NrXpB https://t.co/vsMN3HkSv6
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Did you know?
There is very limited reporting of sex-disaggregated RCT results, data necessary from an FDA standpoint. Dr. L. Eder points out the importance of this data from a clinical standpoint.
Let's do better!
#RNL2024 @RheumNow @lihi_eder https://t.co/3FETZZWt0B
Dr. Rachel Tate uptoTate ( View Tweet)
This is the risk. We have to be aware and better at this in order to serve our female patients better @lihi_eder @RheumNow #RNL2024 https://t.co/7JIDtlSGXh
Richard Conway RichardPAConway ( View Tweet)
The panel addresses the question about using combination biologics and combo tsDMARDS + biologic. These combos are being studied. The panel noted combo apremilast +biologic is pretty commonly used appears to be effective and safe. #RNL2024 @rheumnow https://t.co/EeIlhJiDZU
TheDaoIndex KDAO2011 ( View Tweet)
Dr. Eder noted in her metanalysis of treatment efficacy in PsA based on gender – women had poorer response to treatments; the placebo effects are the same between men and women, suggesting a biologic mechanism and rather than a “psychosomatic” effect. #RNL2024 @rheumnow https://t.co/3H2Nfamg70
Links:
TheDaoIndex KDAO2011 ( View Tweet)